The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

BACKGROUND: Elevated expression of erbB3 receptor has been reported to induce resistance to therapeutic agents, including trastuzumab in erbB2-overexpressing breast cancer. Our recent studies indicate that erbB3 interacts with both erbB2 and IGF-1 receptor to form a heterotrimeric complex in trastuz...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jingcao, Wang, Shuiliang, Lyu, Hui, Cai, Bo, Yang, XiaoHe, Wang, Jianxiang, Liu, Bolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829386/
https://www.ncbi.nlm.nih.gov/pubmed/24215614
http://dx.doi.org/10.1186/1476-4598-12-134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829386/
https://www.ncbi.nlm.nih.gov/pubmed/24215614
http://dx.doi.org/10.1186/1476-4598-12-134

Ejemplares similares